For many people, GLP-1s (e.g. Ozempic, Wegovy, and Mounjaro) have succeeded where traditional approaches may not have been sustainable, reducing appetite, improving glycaemic control and lowering cardiovascular risk. Yet a new clinical challenge is emerging. 

Rapid GLP-1 driven weight loss reduces food intake, causing protein and micronutrient shortfalls that heighten risks of muscle loss and nutritional deficiencies. Despite success on the scales, there is a strong need for structured nutrition to support the GLP-1 journey.

This whitepaper, The GLP-1 Compass, explains how structured nutrition monitoring, microbiome insight and precision dietary intervention can help you to remain strong, nourished, metabolically flexible and resilient during and after GLP-1 therapy.